http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1613298-A4
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a431f1e5f5bd51f2842c97425b320542 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-739 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 |
| filingDate | 2004-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ec2ccc90eb52b104b7eb546a7eeed4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_292ed8605201a149bc3e5b8e9f1fb831 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94dbae791aacb7857a8ed5116b0034e4 |
| publicationDate | 2007-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1613298-A4 |
| titleOfInvention | LYSOPHOSPHATIDE ACID ANALOGUES AND INHIBITION OF NEOINTIMA FORMATION |
| abstract | The phospholipid growth factor lysophosphatidic acids (LPAs) containing unsaturated fatty acids (18:1, 18:2 and 20:4) and fatty alcohols containing hydrocarbon chains with more than 4 carbons were capable of inducing a rapid formation of neointima, an initial step in the development of atherosclerotic plaque. LPAs with saturated fatty acids did not induce neointima formation. A Peroxisome Proliferator-Activated Receptors gamma (PPARϜ)-specific agonist Rosiglitasone also induced a profound formation of neointima. GW9662, a selective and irreversible antagonist of PPARϜ, abolished LPA- and Rosiglitazone-induced neointima formation, indicating that LPA-induced neointima formation requires the activation of PPARϜ. These data suggest that LPA analogs that bind to but do not activate downstream signaling of PPARϜ or antagonists of PPARϜ that inhibit PPARy signaling would be useful in the prevention and/or treatment of neointima formation and atherosclerosis. |
| priorityDate | 2003-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 415.